Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing

BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melanoma and BRAF(V600) mutations. In order to evaluate BRAF tumor heterogeneity between primary and metastatic site, we have evaluated the performance of immunohistochemistry (IHC) with an anti-BRAF(V600E)...

Descripción completa

Detalles Bibliográficos
Autores principales: Boursault, Lucile, Haddad, Véronique, Vergier, Béatrice, Cappellen, David, Verdon, Severine, Bellocq, Jean-Pierre, Jouary, Thomas, Merlio, Jean-Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748080/
https://www.ncbi.nlm.nih.gov/pubmed/23976959
http://dx.doi.org/10.1371/journal.pone.0070826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748080/
https://www.ncbi.nlm.nih.gov/pubmed/23976959
http://dx.doi.org/10.1371/journal.pone.0070826

Ejemplares similares